DSM Biologics to manufacture Morphosys antibody
This article was originally published in Scrip
DSM Biologics is to manufacture Morphosys's fully human HuCAL antibody MOR202, a promising target for the treatment of multiple myeloma. The two firms have signed a biopharmaceutical manufacturing agreement covering process development and cGMP manufacturing of MOR202, though no financial details were disclosed. DSM Biologics will manufacture the compound in its cGMP facilities in Groningen, the Netherlands. DSM Biologics also manufactures Morphosys's MOR103, which targets inflammation. Morphosys will continue to use Crucell's PER C6 technology platform for the large-scale manufacture of biopharmaceuticals.